Cipla Ltd

Cipla Ltd

Cipla Ltd has received US FDA approval for its Abbreviated New Drug Application (ANDA) for Generic Advair Diskus in all three strengths, marking a significant milestone in the company's expansion of complex respiratory capabilities in the US.

Cipla Ltd

Cipla Ltd has announced its Q1 FY27 earnings, with revenue of INR7,100 crores, a record high for the company. The company's One India business achieved a 12% Y-o-Y growth, with strong performance across key therapies, including respiratory, anti-diabetes, cardiac, and urology. The company added 2 new brands to the INR100-plus crores club, taking its total to 33, and has 23 brands in the IPM top 300.

Cipla Ltd

Cipla Ltd has announced the publication of unaudited financial results for the quarter ended 30th June, 2026, in accordance with Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Cipla Ltd

Cipla Ltd has announced the availability of the audio recording of the earnings conference call for the quarter ended 30th June, 2026 on its website.

Cipla Ltd

Cipla Ltd has notified changes in Key Managerial Personnel (KMPs) and Officers under Regulation 30(5) of the SEBI Listing Regulations, effective from July 24, 2026. The changes include new contact details for the Managing Director, Global Chief Financial Officer, Company Secretary, and Chief General Counsel.

Cipla Ltd

Cipla Ltd has announced changes in its Key Managerial Personnel (KMPs) and Officers authorized under Regulation 30(5) of the SEBI Listing Regulations, effective from July 24, 2026.

Cipla Ltd

Cipla Ltd has announced changes in Key Managerial Personnel (KMPs) and Officers authorized under Regulation 30(5) of the SEBI Listing Regulations, effective from 24th July, 2026.

Cipla Ltd

Cipla Ltd has notified changes in Key Managerial Personnel (KMPs) and Officers authorised under Regulation 30(5) of the SEBI Listing Regulations, effective from 24th July, 2026. The changes include new contact details for the Managing Director, Global Chief Executive Officer, Global Chief Financial Officer, Company Secretary, and Chief General Counsel.

Cipla Ltd

Cipla Ltd has announced changes in its Key Managerial Personnel (KMPs) and Officers authorized under Regulation 30(5) of the SEBI Listing Regulations, effective from July 24, 2026.

Cipla Ltd

Cipla Ltd has granted stock options and employee stock appreciation rights to employees under the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021. The company has granted 5,530 stock options and 19,179 employee stock appreciation rights, with vesting periods ranging from 2 to 5 years.

Cipla Ltd

Cipla Ltd has announced a change in management with Mr. Sanjay Joseph, Head - API Business, ceasing to be a Senior Managerial Personnel (SMP) with effect from July 24, 2026.

Cipla Ltd

Cipla Ltd has announced the transition of Mr. Ashish Adukia as Global Chief Financial Officer to an internal business leadership role, and the appointment of Mr. Dinesh Jain as the new Global Chief Financial Officer. Mr. Adukia will relinquish his position effective from 23rd July, 2026, and Mr. Jain will take over on 24th July, 2026.

Cipla Ltd

Cipla Ltd's Board of Directors has approved the transition of Mr. Ashish Adukia to an internal business leadership role, and the appointment of Mr. Dinesh Jain as Global Chief Financial Officer and Key Managerial Personnel. Mr. Adukia has relinquished his position as Global Chief Financial Officer, and Mr. Jain will take over the role from July 24, 2026.

Cipla Ltd

Cipla Ltd announced its Q1FY27 financial results, with a 12% YoY growth in revenue, driven by a solid growth in One-India business and a robust growth in Branded Prescription business. The company delivered a net cash position of INR 9,494 Cr and a strong R&D investments of INR 486 Cr, accounting for 6.8% of sales. The company also announced the launch of new products and the expansion of its presence in high-growth therapy areas.

Cipla Ltd

Cipla Ltd has announced its Q1FY27 results, with revenue of INR 7,119 Cr, EBITDA of INR 1,192 Cr, and PAT of INR 789 Cr. The company has reported a 16.7% EBITDA margin and 11.1% PAT margin. Cipla has maintained its #2 rank in the overall chronic segment and has launched four new products in Q1FY27.

Cipla Ltd

Cipla Ltd has announced its unaudited financial results for the quarter ended 30th June, 2026, with a net profit of ₹785.55 crores and a revenue from operations of ₹7,119.28 crores.